Department of Dermatology, Venereology and Allergology, Faculty of Medicine, Medical University of Gdansk, Smoluchowskiego 17, 80-214 Gdansk, Poland.
Molecules. 2022 May 13;27(10):3143. doi: 10.3390/molecules27103143.
Botulinum toxin (BoNT) is a neurotoxin produced by the bacteria. Among seven different isoforms, only BoNT-A and BoNT-B are commercially used. Currently, botulinum toxin has been indicated by the U.S. Food and Drug Administration in several disorders, among others: chronic migraine, hyperhidrosis, urinary incontinence from detrusor overactivity, or cosmetics. However, there are numerous promising reports based on off-label BTX usage, indicating its potential effectiveness in other diseases, which remains unknown to many. Among them, dermatological conditions, such as rosacea, annal fissure, Raynaud phenomenon, hypertrophic scars and keloids, and also hidradenitis suppurativa, are currently being investigated. This article aims to provide a comprehensive update on the off-label use of botulinum toxin in dermatology, based on an analysis and summary of the published literature.
肉毒毒素（BoNT）是由细菌产生的神经毒素。在七种不同的亚型中，只有 BoNT-A 和 BoNT-B 被商业化应用。目前，肉毒毒素已被美国食品和药物管理局批准用于多种疾病的治疗，包括慢性偏头痛、多汗症、逼尿肌过度活动引起的尿失禁或美容等。然而，有许多基于 BoNT 超适应证使用的有前途的报告，表明其在其他疾病中的潜在有效性，而许多人对此并不了解。其中，皮肤科疾病，如酒渣鼻、肛裂、雷诺现象、肥厚性瘢痕和瘢痕疙瘩以及化脓性汗腺炎，目前正在研究中。本文旨在根据已发表文献的分析和总结，提供肉毒毒素在皮肤科超适应证使用的全面更新。
